Royce & Associates’s Bioventus BVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.23M | Buy |
1,092,076
+199,860
| +22% | +$1.32M | 0.07% | 385 |
|
|
2025
Q1 | $8.16M | Buy |
892,216
+159,980
| +22% | +$1.46M | 0.09% | 333 |
|
|
2024
Q4 | $7.69M | Buy |
732,236
+34,540
| +5% | +$363K | 0.07% | 396 |
|
|
2024
Q3 | $8.34M | Buy |
+697,696
| New | +$8.34M | 0.08% | 361 |
|
|
2023
Q4 | – | Sell |
-50,000
| Closed | -$165K | – | 871 |
|
|
2023
Q3 | $165K | Hold |
50,000
| – | – | ﹤0.01% | 883 |
|
|
2023
Q2 | $145K | Hold |
50,000
| – | – | ﹤0.01% | 891 |
|
|
2023
Q1 | $53.5K | Sell |
50,000
-191,306
| -79% | -$205K | ﹤0.01% | 907 |
|
|
2022
Q4 | $630K | Sell |
241,306
-1,854,879
| -88% | -$4.84M | 0.01% | 806 |
|
|
2022
Q3 | $14.7M | Buy |
2,096,185
+137,400
| +7% | +$962K | 0.17% | 165 |
|
|
2022
Q2 | $13.4M | Buy |
1,958,785
+15,602
| +0.8% | +$106K | 0.14% | 214 |
|
|
2022
Q1 | $27.4M | Buy |
1,943,183
+154,978
| +9% | +$2.19M | 0.23% | 105 |
|
|
2021
Q4 | $25.9M | Buy |
+1,788,205
| New | +$25.9M | 0.19% | 145 |
|